Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Besses

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
How to Treat Essential Thrombocythemia and Polycythemia VeraCarlos Besses, Alberto Alvarez-Larrán
Current Hematologic Malignancy Reports|August 15, 2014
Antiplatelet therapy in the management of myeloproliferative neoplasmsAlberto Alvarez-Larrán, Carlos Besses
Annals of Hematology|March 9, 2019
Thromboembolic events in polycythemia veraMartin Griesshammer, Jean-Jacques Kiladjian, Carlos Besses
Medicina Clinica|March 16, 2013
[Treatment of essential thrombocythemia]Alberto Alvarez-Larrán, Francisco Cervantes, Carlos Besses
Leukemia Research|October 18, 2011
Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasmsAlberto Alvarez-Larrán, Anna Angona, Luz Martínez-Avilés, et al.
Annals of Hematology|September 10, 2011
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasmsLuz Martínez-Avilés, Carlos Besses, Alberto Álvarez-Larrán, et al.
British Journal of Haematology|April 13, 2013
Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational studyAlberto Alvarez-Larrán, Arturo Pereira, Eduardo Arellano-Rodrigo, et al.
Medicina Clinica|June 9, 2009
[Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia]Manuel Giralt, Victor Navas, Luis Hernández-Nieto, et al.
Clinical Drug Investigation|November 28, 2012
Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS studyJean-Jacques Kiladjian, Carlos Besses, Martin Griesshammer, et al.
European Journal of Haematology|July 22, 2006
Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institutionAntonio Salar, Dolors Casao, Marta Cervera, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
How to Treat Essential Thrombocythemia and Polycythemia VeraCarlos Besses, Alberto Alvarez-Larrán
Current Hematologic Malignancy Reports|August 15, 2014
Antiplatelet therapy in the management of myeloproliferative neoplasmsAlberto Alvarez-Larrán, Carlos Besses
Annals of Hematology|March 9, 2019
Thromboembolic events in polycythemia veraMartin Griesshammer, Jean-Jacques Kiladjian, Carlos Besses
Medicina Clinica|March 16, 2013
[Treatment of essential thrombocythemia]Alberto Alvarez-Larrán, Francisco Cervantes, Carlos Besses
Leukemia Research|October 18, 2011
Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasmsAlberto Alvarez-Larrán, Anna Angona, Luz Martínez-Avilés, et al.
Annals of Hematology|September 10, 2011
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasmsLuz Martínez-Avilés, Carlos Besses, Alberto Álvarez-Larrán, et al.
British Journal of Haematology|April 13, 2013
Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational studyAlberto Alvarez-Larrán, Arturo Pereira, Eduardo Arellano-Rodrigo, et al.
Medicina Clinica|June 9, 2009
[Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia]Manuel Giralt, Victor Navas, Luis Hernández-Nieto, et al.
Clinical Drug Investigation|November 28, 2012
Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS studyJean-Jacques Kiladjian, Carlos Besses, Martin Griesshammer, et al.
European Journal of Haematology|July 22, 2006
Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institutionAntonio Salar, Dolors Casao, Marta Cervera, et al.
Pageof 5